Kimberly-Clark holds investor calls ahead of bond sale for Kenvue acquisition

Kenvue: Kenvue is a consumer health company formerly part of Johnson & Johnson, with iconic brands such as Tylenol pain relievers. It is the target of Kimberly-Clark's pending acquisition, which aims to create a combined global health and personal care entity. Recent developments include EU approval of the transaction subject to divestiture conditions and preparatory steps for debt alignment ahead of closing. Kimberly-Clark: Kimberly-Clark is a global consumer packaged goods company focused on personal care, hygiene, and health products including Huggies diapers and Kleenex tissues. It is actively pursuing the acquisition of Kenvue to broaden its portfolio into over-the-counter consumer health brands. The company recently received conditional EU regulatory clearance for the deal and is preparing financing measures including potential bond sales as closing approaches. Deal Timeline: The acquisition is positioned to close later in the fourth quarter of 2026 following recent regulatory progress and debt exchange activities. Financing Activity: Kimberly-Clark is holding investor calls ahead of a potential multi-tranche bond sale to support funding needs tied to the nearing Kenvue acquisition close. Regulatory Approval: The European Commission granted conditional approval to Kimberly-Clark's acquisition of Kenvue after the buyer committed to divesting tampon and feminine hygiene brands in the European Economic Area.